Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to tame After-Meal fat spikes in High-Risk patients

NCT ID NCT07199309

Disease control Sponsor: Marea Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tests whether the drug MAR001 can lower blood fat levels after a meal in adults with high triglycerides. Thirty participants will receive either MAR001 or a placebo injection. The main goal is to see if MAR001 reduces the rise in triglycerides and remnant cholesterol after eating.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MAR001 (a drug given as a shot under the skin)
What this could lead to
If it works, this could lead to a new treatment to lower high fat levels in the blood after eating, potentially reducing heart disease risk.
What could go wrong
This is an early Phase 2 trial with only 30 people, so results may not apply to everyone. The drug may not lower fat levels better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willingness to provide informed consent and comply with the intervention and all study assessments * Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period * HbA1c ≥ 5.7% and ≤ 8.5% * Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study * Stable drug regimen (appropriate if relevant) prior to screening visit and no planned changes during screening or trial participation Exclusion Criteria: * Acute or chronic liver disease * Diabetes medications (other than metformin) * History of type 1 diabetes mellitus or history of diabetic ketoacidosis * Newly diagnosed T2DM * Participants with known active hepatitis A, B, or C * Participants who are known to have uncontrolled human immunodeficiency virus (HIV) infection * Uncontrolled hypothyroidism * Any condition that prevents the participant from complying with study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertriglyceridemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertriglyceridemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Marea Site 301

    RECRUITING

    Chula Vista, California, 91911, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.